[HT-06] Hot Topics 06「Understanding and intervening cerebellar ataxias」

[HT-06-2] European research for disease-modifying trials in SCA3

Thomas Klockgether^1,2 (1.Department of Neurology, University of Bonn, Germany, 2.German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany)

Name: Thomas Andreas Klockgether

Education, Training, and Appointments
1974 - 1980 University of Göttingen, Medical School
1981 - 1983 Internship (Internal Medicine, Anesthesiology) Oldenburg
1983 - 1987 Post-Doc, Max-Planck-Institute, Göttingen
1987 - 1991 Resident, Dept. of Neurology, University of Tübingen
1991 - 1998 Senior Physician and Lecturer, Dept. of Neurology, University of Tübingen
1998 - 2024 Professor of Neurology and Clinical Director, University of Bonn
2008 -2011 Dean of the Medical Faculty, University of Bonn
2011 - 2025 Director of Clinical Research, DZNE

Academic and Professional Duties
1999 - 2002 Head of the German Parkinson´s disease Gene Bank (BMBF)
2001 - 2007 Coordinator of the Collaborative Research Group “Molecular
Pathogenesis of SCA3” (DFG)
2004 - 2009 Coordinator of the EUROSCA Clinical Project (EU FP6)
2004 - 2008 Section Editor Experimental Neurology
2007 - 2014 Speaker of the Clinical Research Group “Innate Immunity in
Neurodegeneration” (DFG)
2008 Coordinator of the European RISCA Study (E-Rare)
2011 - 2019 Speaker of the Centre for Rare Diseases Bonn (ZSEB)
2015 Coordinator of the European SCA3/MJD Inititative (ESMI, JPND)
2015 - 2023 Head of Bonn International Graduate School Clinical and Population Science
2018 Speaker of the Ataxia Global Steering Committee (AGI)